The extent to which individual antiretrovirals penetrate the central nervous system may influence whether those drugs improve cognitive function, but the jury's still out.
Mild cognitive dysfunction is common in HIV-infected patients, even those who have achieved virologic suppression on antiretroviral therapy (ART; JW Infect Dis Dec 15 2010). Such impairment might be related to ongoing HIV replication in the central nervous system (CNS; JW AIDS Clin Care Dec 6 2010), perhaps because of inadequate penetration of antiretrovirals. To assess the relation between ART penetration and cognitive status, investigators evaluated data from a cohort of HIV-infected patients drawn from 26 clinical trials. These patients, who were receiving various antiretroviral regimens, underwent neurocognitive assessments every 48 weeks.
Assessments were included for analysis only if the patient had an undetectable plasma viral load at…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)